Not yet recruitingPhase 1NCT06357377

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

Studying Choroid plexus carcinoma

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Neonc Technologies, Inc.
Principal Investigator: Thomas Chen, MD, PhD
NeOnc Technologies Holdings, Inc.
Intervention: NEO100(drug)
Enrollment: 12 enrolled
Eligibility: 5-18 years · All sexes
Timeline: 2026 – 2026

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06357377 on ClinicalTrials.gov

← Back to all trials